Business Context and Reporting Period
Company: Streamex Corp. (formerly BioSig Technologies, Inc.)
Reporting Period: Quarter ended September 30, 2025 (Q3 2025)
Business Overview: The Company transitioned from a medical device technology focus to a diversified technology platform following the acquisition of Streamex Exchange Corporation on May 28, 2025. Streamex Exchange is a software development company focused on blockchain-based infrastructure for tokenizing real-world assets (RWAs), specifically gold-backed financial products. The Company operates as a single reportable segment.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9 Months 2025 | 9 Months 2024 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $27 |
| Net Loss (Attributable to Common Stockholders) | $(15,586) | $(1,940) | $(38,774) | $(9,395) |
| Operating Expenses | $6,113 | $2,950 | $29,461 | $11,706 |
| Cash and Cash Equivalents (End of Period) | $11,045 | $615 | $11,045 | $615 |
| Working Capital Deficit | $(110,608) | $(1,920) | $(110,608) | $(1,920) |
| Derivative Liability (Exchangeable Shares) | $115,712 | $0 | $115,712 | $0 |
| Goodwill | $69,888 | $0 | $69,888 | $0 |
Note: All figures in thousands except per share data. Net loss per common share (basic and diluted) was $(0.47) for Q3 2025 and $(1.42) for the nine months ended September 30, 2025.
Material Changes vs. Prior Period
- Acquisition Impact: The acquisition of Streamex Exchange resulted in the recognition of $69.9 million in goodwill and $45.4 million in intangible assets. This drove a significant increase in depreciation and amortization expenses to $1.5 million for Q3 2025 (up from $31k in Q3 2024).
- Derivative Liability: A $115.7 million derivative liability was recorded for Exchangeable Shares issued to Streamex Exchange shareholders. This liability increased by $10.2 million during Q3 2025 due to fair value adjustments, contributing significantly to the net loss.
- Operating Expenses: General and Administrative (G&A) expenses surged to $4.6 million in Q3 2025 (up from $2.8 million in Q3 2024), primarily due to stock-based compensation ($15.6 million for the nine months), professional fees, and finder's fees ($6.0 million) related to the acquisition.
- Liquidity: Cash balances increased to $11.0 million from $142k at year-end 2024, driven by financing activities including a public offering and ATM sales, despite a $7.4 million cash burn from operations over the nine-month period.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: Management has raised substantial doubt about the Company's ability to continue as a going concern due to a working capital deficit of approximately $111 million and a history of net losses. Additional financing is required to fund operations.
- Subsequent Events (Post-Sept 30, 2025):
- Shareholder Approval: On November 4, 2025, shareholders approved the issuance of common stock for the Exchangeable Shares. Consequently, the derivative liability was reclassified to permanent equity, and the conversion cap was removed.
- Debt Financing: On November 4, 2025, the Company closed the first tranche of a Secured Convertible Debenture with Yorkville for $25 million principal (approx. $24 million proceeds), with $12.6 million allocated to purchase gold bullion as collateral.
- Internal Controls: Management identified material weaknesses in internal controls over financial reporting, specifically regarding stock-based compensation, period-end review processes, segregation of duties, and accounting for business combinations.
- Unusual Items: The financial statements include a $10.2 million non-cash loss from the change in fair value of the derivative liability and a $765k income tax benefit resulting from the reversal of a deferred tax liability related to the acquisition.
Investor Verification Checklist
- Derivative Liability Reclassification: Verify the impact of the November 4, 2025 shareholder approval on the balance sheet, specifically the removal of the $115.7 million derivative liability and its reclassification to equity.
- Debt Covenants and Collateral: Review the terms of the $25 million convertible debenture closed in November 2025, including the requirement to hold gold bullion as collateral and the conversion price mechanics.
- Going Concern Mitigation: Assess the sufficiency of the $11 million cash balance and the $1 billion Standby Equity Purchase Agreement (SEPA) with Yorkville to fund operations through the next 12 months.
- Stock-Based Compensation: Scrutinize the $15.6 million in stock-based compensation expenses for the nine months ended September 30, 2025, and the valuation assumptions used for the Exchangeable Shares.
- Internal Control Remediation: Monitor the Company's progress in remediating the identified material weaknesses in internal controls over financial reporting.